Pluri (PLUR) Institutional Ownership : 0.54% (As of Apr. 30, 2024)

View and export this data going back to 1991. Start your Free Trial

What is Pluri Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Pluri's institutional ownership is 0.54%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Pluri's Insider Ownership is 23.29%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Pluri's Float Percentage Of Total Shares Outstanding is 95.49%.

Pluri Institutional Ownership Historical Data

The historical data trend for Pluri's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pluri Institutional Ownership Chart

Pluri Historical Data

The historical data trend for Pluri can be seen below:

	2023-06-30	2023-07-31	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31
Institutional Ownership	0.65	0.68	0.68	0.53	0.51	0.53	0.54	0.54	0.54	0.54

Pluri Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Pluri (PLUR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pluri Inc (NAS:PLUR) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

Y55:Germany

Address

MATAM Advanced Technology Park, Building No.5, Haifa, ISR, 3508409

Website

https://www.pluri-biotech.com

Pluri Inc is a biotechnology company, that creates cell-based products for commercial use and is pioneering a biotech revolution that promotes wellbeing and sustainability. The company's technology platform developed a three-dimensional, or 3D, technology platform for cell expansion with an industrial scale in-house Good Manufacturing Practice, or GMP, cell manufacturing facility.

Executives

Lorne Kenneth Abony	director	MATAM PARK, BUILDING #5, HAIFA L3 3508409
Zami Aberman	officer: Chief Executive Officer	63 RABUTZKY STREET, RAANANA L3 43220
Varda Shalev	director	MATAM PARK, BUILDING #5, HAIFA L3 3508409
Pinhas Doron Birger	director	MATAM PARK, BUILDING #5, HAIFA L3 3508409
Clover Wolf Capital - Limited Partnership	10 percent owner	BOODENHIMER 24, TEL AVIV L3 6200838
Rami Avraham Levi	director	MATAM ADVANCED TECHNOLOGY PARK, BUILDING NO. 5, HAIFA L3 3508409
Maital Shemesh-rasmussen	director	MATAM ADVANCED TECHNOLOGY PARK, BUILDING NO. 5, HAIFA L3 3508409
Doron Shorrer	director	33 KOREH PLADORR ST, JERUSALEM L3 93393
Isaac Braun	director	9 ZEHARIA STREET, BENE BARAK L3 51540
Yaky Yanay	officer: Chief Financial Officer	ARGAMAN 14, SHIMSHIT L3 17906
Moria Kwiat	director	HAKFAR 11, KIRYAT ONO L3 55525
Israel Ben-yoram	director	24 BARKAN STREET, RISHON LEZION L3 00000
Chen Franco-yehuda	officer: Chief Financial Officer	MATAM ADVANCED TECHNOLOGY PARK, BUILDING NO. 5, HAIFA L3 31905
Mark Germain	director	WELLSFORD REAL PROPERTIES INC, 535 MADISON AVENUE, NEW YORK NY 10022
Erez Egozi	officer: Chief Financial Officer	MATAM PARK, BUILDING 05, HAIFA L3 31905